(90)Y-PET/CT Imaging Quantification for Dosimetry in Peptide Receptor Radionuclide Therapy: Analysis and Corrections of the Impairing Factors.

Purpose: We evaluated the possibility to assess (90)Y-PET/CT imaging quantification for dosimetry in (90)Y-peptide receptor radionuclide therapy.

Methods: Tests were performed by Discovery 710 Elite (GE) PET/CT equipment. A body-phantom containing radioactive-coplanar-spheres was filled with (90)Y water solution to reproduce different signal-to-background-activity-ratios (S/N).

Cryotherapy for breast cancer: a feasibility study without excision.

Purpose: To assess the feasibility of percutaneous multiprobe breast cryoablation (BC) for diverse presentations of cancers that remained in situ after BC.

Materials And Methods: After breast magnetic resonance (MR) imaging and thorough consultation, patients underwent BC after giving informed consent. This study was approved by the institutional review board.

Quantitative analysis of 90Y Bremsstrahlung SPECT-CT images for application to 3D patient-specific dosimetry.

Aim: The aim of this study was to evaluate the accuracy of the activity quantification of single-photon emission computed tomography/computed tomography (SPECT-CT) (90)Y-Bremsstrahlung images and to validate the S-voxel method.

Methods: An anthropomorphic torso phantom with radioactive inserts ((90)Y) was acquired by SPECT-CT. Constant calibration factors (cps/MBq) for the quantification were evaluated, considering different volume, shape, position inside the phantom, activity concentration and background, and distance from detectors.

Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura.

Malignant solitary fibrous tumor (MSFT) of the pleura is a rare neoplasm, with unpredictable biologic behavior and a low sensitivity to chemotherapy. To the authors' knowledge, no other effective medical treatment is available for this disease. Imatinib mesylate is a tyrosine kinase inhibitor targeting the platelet-derived growth factor (PDGFR-alpha and PDGFR-beta), the BCR-ABL, and c-KIT receptors.